Goldman Sachs Group Inc Larimar Therapeutics, Inc. Put Options Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding LRMR
# of Institutions
114Shares Held
60.9MCall Options Held
1.37MPut Options Held
124K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$161 Million3.33% of portfolio
-
Janus Henderson Group PLC London, X04.02MShares$30.5 Million0.02% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.99MShares$30.3 Million8.04% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$25.9 Million6.65% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.37MShares$18 Million0.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $328M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...